{"id":3323,"date":"2026-09-21T09:00:00","date_gmt":"2026-09-21T13:00:00","guid":{"rendered":"https:\/\/www.insilens.com\/?p=3323"},"modified":"2026-09-21T20:18:21","modified_gmt":"2026-09-22T00:18:21","slug":"cue-221-shows-dose-consistent-activity-in-chinese-urticaria-study","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=3323","title":{"rendered":"CUE-221 Shows Dose-Consistent Activity in Chinese Urticaria Study"},"content":{"rendered":"

\"\"<\/p>\n

Company<\/strong><\/p>\n

Cue Biopharma<\/p>\n

Event Type<\/strong><\/p>\n

Phase 2 Clinical Readout<\/p>\n

Modality<\/strong><\/p>\n

Humanized IgG1 Anti-IgE Antibody<\/p>\n

Asset<\/strong><\/p>\n

CUE-221 (UB-221)<\/p>\n

Target<\/strong><\/p>\n

Free IgE (Preserving IgE-CD23 Engagement)<\/p>\n

Disease Area<\/strong><\/p>\n

Chronic Spontaneous Urticaria<\/p>\n

Summary<\/h4>\n

Cue Biopharma disclosed positive topline results from a 145-participant randomized double-blind Phase 2 study of CUE-221, also called UB-221, conducted in China by Genesis Life Sciences. Complete weekly hive score resolution at Week 12 occurred in 43% to 54% across doses versus 11% with placebo. A descriptive omalizumab arm reached 41%. The study supports further development but was not powered for a direct comparison with omalizumab.<\/p>\n

Participants had moderate-to-severe chronic spontaneous urticaria inadequately controlled by H1 antihistamines. All CUE-221 dose groups met the primary HSS7 complete resolution endpoint and the UAS7 complete response secondary endpoint, with UAS7 complete response rates of 38% to 46% versus 11% placebo. The company reported continued responses after treatment, including high-dose HSS7 complete resolution of 60% at Week 28 versus 24% in the descriptive omalizumab arm.<\/p>\n

No treatment-related serious adverse events, hypersensitivity, or anaphylaxis were reported, and injection site reactions were described as infrequent. Full adverse event counts, multiplicity controls, baseline balance, rescue medication, dose-level sizes, and China registry details were not disclosed in the release. Cue licensed ex-China rights from Ascendant; Genesis retains China, Hong Kong, Macau, and Taiwan rights.<\/p>\n

Deep Analysis<\/h4>\n

One interpretation is that dual neutralization of free IgE and preservation of IgE-CD23 engagement can suppress new IgE synthesis and extend response beyond dosing. Dose-consistent placebo separation and post-treatment durability are supportive. The countercase is that the proposed synthesis effect was not quantified in the disclosure, and delayed response can reflect disease fluctuation, treatment carryover, or subgroup imbalance.<\/p>\n

A second interpretation is that CUE-221 can compete with omalizumab. The active arm offers context, but the study was not powered for head-to-head inference, confidence intervals were not presented, and regional practice or population differences can affect portability. Global development must reproduce benefit under prespecified statistical testing and characterize immunogenicity, anaphylaxis, and long-term immune consequences.<\/p>\n

Company and Product Background<\/h4>\n

Cue Biopharma develops immunotherapies and licensed rest-of-world rights to CUE-221 from Ascendant Health. Chronic spontaneous urticaria causes recurrent hives and angioedema without a consistent external trigger. CUE-221 is a humanized IgG1 anti-IgE antibody designed to neutralize free IgE while maintaining IgE binding to CD23 on B cells, with the intent of reducing additional IgE synthesis.<\/p>\n

Signal Extraction<\/h4>\n
    \n
  • China clinical signal: 145 participants in a randomized placebo- and active-comparator Phase 2 study.<\/li>\n
  • Week 12 HSS7 complete resolution: 43% to 54% versus 11% placebo.<\/li>\n
  • Comparator limitation: omalizumab results were descriptive, not a powered superiority test.<\/li>\n
  • Cross-border structure: Cue controls rest-of-world rights; Genesis retains Greater China rights.<\/li>\n
  • Upgrade path: a registered global Phase 2b or 3 with direct omalizumab comparison, sustained off-treatment IgE suppression, and replicated safety.<\/li>\n
  • Falsifier: loss of placebo separation, no biomarker support for the dual mechanism, or hypersensitivity risk at scale in a global study.<\/li>\n<\/ul>\n

    InSilens Take<\/h4>\n

    This is a material positive China-originated readout with cross-border implications because the efficacy signal was randomized and dose-consistent. Claims of a functional cure or superiority to Xolair are not established. The value inflection will come from a globally registered comparative study with transparent multiplicity, biomarker, and safety data.<\/p>\n

    Signal Assessment<\/h4>\n

    Signal importance is moderate-to-high given the randomized dose-consistent efficacy signal and cross-border licensing structure. Direction is positive based on the disclosed endpoints. Confidence in the underlying facts is high for the company-reported randomized endpoints, while confidence in interpretation is moderate-low because the active comparison was descriptive, registry transparency is limited, and independent or peer-reviewed confirmation is unavailable.<\/p>\n","protected":false},"excerpt":{"rendered":"

    Cue Biopharma disclosed positive topline results from a 145-participant randomized double-blind Phase 2 study of CUE-221, also called UB-221, conducted in China by Genesis Life Sciences. Complete weekly hive score resolution at Week 12…<\/p>\n","protected":false},"author":1,"featured_media":3341,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1,11,3],"tags":[823,822,821],"class_list":["post-3323","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-all-categories","category-clinical","category-therapeutic-indication","tag-anti-ige-antibody","tag-chronic-spontaneous-urticaria","tag-cue-biopharma"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3323","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=3323"}],"version-history":[{"count":2,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3323\/revisions"}],"predecessor-version":[{"id":3346,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3323\/revisions\/3346"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/3341"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=3323"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=3323"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=3323"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}